Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients.
Mycophenolate mofetil (MMF), an ester prodrug of mycophenolic acid (MPA), is widely used as a maintenance immunosuppressive regimen in solid organ transplant patients. It is increasingly used for the prophylaxis and treatment of graft-versus-host disease (GVHD) in hematopoietic stem cell transplantation (HSCT) patients. MPA displays extensive binding to serum albumin and glucuronidation to the inactive MPA-7-O-glucuronide (MPAG). Here, we review and discuss the pertinent information regarding the clinical pharmacokinetics of MPA in HSCT patients. The pharmacokinetics of MPA are altered in HSCT patients with lower oral bioavailability, shorter half-life and higher clearance than those in healthy volunteers and renal transplant recipients. Moreover, clearance may be increased in young pediatric patients. The optimal MMF dosing and preferred targets are still under investigation in HSCT patients due to the substantial intra- and inter-individual pharmacokinetic variability of MPA and broad range of transplants (malignant vs. nonmalignant, related vs. unrelated donor, and human leukocyte antigen mismatch). The complex pharmacokinetics of MPA have partly hampered the efficient use of MMF, and pharmacokinetic studies in HSCT patients have been limited in size and mostly inconclusive. Future research should be multi-institutional and focus on developing clinical decisions with adequate statistical power to improve clinical care of HSCT recipients.
Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, 1441 Moursund Street, Houston, TX, 77030, USA. dzhang11@uh.edu.
Daping
D
Zhang
Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, 1441 Moursund Street, Houston, TX, 77030, USA.
Diana S-L
DS
Chow
D001682:Biological Availability; D006086:Graft vs Host Disease / Q000517:prevention & control; D006207:Half-Life; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D016030:Kidney Transplantation / Q000379:methods; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011355:Prodrugs
D007166:Immunosuppressive Agents; D011355:Prodrugs; D009173:Mycophenolic Acid
Cancer Chemother Pharmacol. 2015 Feb;75(2):393-400
25542268
Bone Marrow Transplant. 2008 Jul;42(2):113-20
18362900
Biol Blood Marrow Transplant. 2013 Aug;19(8):1159-66
23660171
Biol Blood Marrow Transplant. 2012 Jul;18(7):989-1006
22155504
Ther Drug Monit. 2006 Apr;28(2):145-54
16628123
Biol Blood Marrow Transplant. 2014 Aug;20(8):1121-9
24727337
Clin J Am Soc Nephrol. 2007 Sep;2(5):1062-72
17702714
Am J Transplant. 2004 Dec;4(12 ):2045-51
15575908
Transplantation. 1999 Feb 27;67(4):499-504
10071016
Clin Pharmacokinet. 1998 Jun;34(6):429-55
9646007
Biol Blood Marrow Transplant. 2009 Sep;15(9):1134-9
19660728
Drug Metab Pharmacokinet. 2014;29(1):4-11
24351871
Br J Clin Pharmacol. 2013 Jan;75(1):45-59
22519685
J Clin Pharmacol. 2009 Oct;49(10 ):1196-201
19783713
Blood. 2009 Jul 16;114(3):511-7
19443659
Anal Chem. 2012 Jan 3;84(1):216-23
22092180
Ther Drug Monit. 2010 Oct;32(5):606-14
20720518
Clin Pharmacol Ther. 2005 Nov;78(5):486-500
16321615
Ann Pharmacother. 2008 Jul;42(7):1037-47
18594053
Bone Marrow Transplant. 2009 Jul;44(2):113-20
19151792
J Clin Pharmacol. 2008 Apr;48(4):485-94
18296555
Ther Drug Monit. 2007 Feb;29(1):122-6
17304160
Biol Blood Marrow Transplant. 2004 Apr;10 (4):246-58
15077223
Biol Blood Marrow Transplant. 2010 Mar;16(3):421-9
19925875
J Clin Pharmacol. 2011 Mar;51(3):309-20
20418509
J Clin Pharmacol. 2013 Apr;53(4):393-402
23382105
Clin Pharmacokinet. 2007;46(1):13-58
17201457
Clin Biochem. 2000 Apr;33(3):203-8
10913519
Clin Transplant. 2014 Sep;28(9):980-9
24943923
Ther Drug Monit. 2006 Jun;28(3):394-401
16778725
Br J Clin Pharmacol. 2001 Nov;52(5):605-9
11736871
J Clin Pharmacol. 1996 Apr;36(4):315-24
8728345
J Clin Pharmacol. 2012 Nov;52(11):1665-75
22110162
Biol Blood Marrow Transplant. 2005 Jul;11(7):495-505
15983549
Kidney Int. 2002 Sep;62(3):1060-7
12164891
Clin Transplant. 2011 Mar-Apr;25(2):222-7
20201951
Br J Clin Pharmacol. 2010 Oct;70(4):567-79
20840448
Toxicol Pathol. 1995 Mar-Apr;23(2):115-23
7569664
Int J Hematol. 2012 Jul;96(1):10-25
22592321
Am J Transplant. 2005 May;5(5):987-94
15816878
Clin Transplant. 2001 Jun;15(3):176-84
11389708
Int J Hematol. 2008 Jul;88(1):104-10
18473127
Int J Clin Pharmacol Ther. 2013 Sep;51(9):711-7
23782584
J Clin Pharmacol. 2007 Jan;47(1):6-12
17192496
Blood. 2005 Dec 15;106(13):4381-8
16144801
Br J Clin Pharmacol. 2011 Jun;71(6):807-14
21204908
Clin Pharmacokinet. 1984 Jan;9 Suppl 1:10-7
6705422
Clin Biochem. 1998 Jul;31(5):317-22
9721428
Br J Clin Pharmacol. 2008 Jun;65(6):893-907
18279479
Bone Marrow Transplant. 2015 Feb;50(2):165-72
25347008
Ther Drug Monit. 1995 Dec;17 (6):681-4
8588241
J Clin Pharmacol. 2005 Feb;45(2):219-26
15647415
Ther Drug Monit. 2007 Jun;29(3):353-60
17529894
Biol Blood Marrow Transplant. 2010 Mar;16(3):333-43
19835971
Pharmacogenet Genomics. 2014 Jan;24(1):73-9
24220207
Br J Clin Pharmacol. 2013 Feb;75(2):463-75
22765258
Clin J Am Soc Nephrol. 2007 Jan;2(1):184-91
17699403